The role of angiotensin II receptor antagonists in the management of diabetes

Blood Pressure, Supplement

Volumn 10, Issue 1, 2001, Pages 21-26

  Barnett, A H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Angiotensin II receptor antagonists; Diabetic nephropathy; Telmisartan; Type II diabetes

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; TELMISARTAN;

ADULT; AGED; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG RECEPTOR BINDING; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0035075350     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370501750066471     Document Type: Conference Paper

References (41)

1. Blood pressure control, microalbuminuria and cardiovascular risk in type 2 diabetes mellitus
2. Diabetic hypertensive patients. Is this a group in need of particular care and attention?
3. Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus
4. Diabetic nephropathy in type II diabetes
5. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions
6. Pathogenesis of diabetic microangiopathy. The hemodynamic view
7. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy
8. Pathobiochemical aspects of diabetic nephropathy
9. ACE inhibitors and diabetic nephropathy: Clinical and experimental findings
10. The impact of a family history of type II (non-insulin-dependent) diabetes mellitus on the risk of diabetic nephropathy in patients with type I (insulin-dependent) diabetes mellitus
11. Risk factors for nephropathy in type 2 diabetes mellitus
12. Nephropathy in type 2 diabetes
13. Smoking as a risk factor for nephropathy in non-insulin-dependent diabetics
14. Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus
15. Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study
16. Predicting diabetic nephropathy in insulin-dependent patients
17. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy
18. Diabetes and hypertension
19. Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy
20. Renoprotective role of ACE inhibitors in diabetic nephropathy
21. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
22. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One-year analysis
23. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients
24. Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria
25. Long-term effects of angiotensin converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients
26. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
27. Short and long term effects of antihypertensive therapy in the diabetic rat
28. The molecular basis of increased glomerulosclerosis after blockade of the renin angiotensin system in growth hormone transgenic mice
29. Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction
30. Mesangial matrix modulation and glomerulosclerosis
31. Physiologic and pharmacologic implications of AT1 versus AT2 receptors
32. Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system
33. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart
34. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart
35. Angiotensin II receptor blockers: Review of the binding characteristics
36. Angiotensin II receptor blockade in TGR(mREN2)27: Effects of renin-angiotensin-system gene expression and cardiovascular functions
37. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade
38. 1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain
39. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus
40. The Irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics
41. Angiotensin II AT1 receptor antagonists: Clinical development and future perspectives